Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...
Six months of prevention -- that's how long Lenacapavir, the new drug for HIV prevention lasts. The Food and Drug Administration approved it last month, and despite its price tag, HIV Alliance says it ...
The HIV-prevention pill PrEP will now be covered under most insurance plans. Its name is short for pre-exposure prophylaxis. Supporters of the move to make it free to those who are insured call it a ...
July 13, 2011 — In another major advance against the spread of HIV/AIDS, 2 studies released today report that a daily dose of antiretroviral drugs used to treat HIV infection also can reduce the ...
Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...
Please provide your email address to receive an email when new articles are posted on . Survey results showed that transgender women and transfeminine nonbinary people support OTC PrEP. Lauren ...
Nearly one in three gay and bisexual men who were diagnosed with HIV at UK sexual health clinics didn't meet the criteria for "high risk" that would signal to a clinician that they would be good ...
Avoidable HIV infections and net health care costs would rise if coverage of pre-exposure prophylaxis (PrEP) were to be reduced even a moderate amount, according to a study published in JAMA Network ...
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to disrupt the pre-exposure prophylaxis (PrEP) market with a twice-yearly ...
Ibrahim Lwingi lost many family members to HIV/AIDS and says he likely would've been next without prevention meds from ...